DQHK(SZ:000985)2025-09-16 06:38Group 1: Investor Relations Activities - The investor relations activity was conducted via an online platform on September 12, 2025, from 15:00 to 16:00 [2] - Key participants included the Chairwoman Zhang Caihong, General Manager Dou Yan, and Financial Director Wu Yunfeng [2] - The company addressed various investor questions during the earnings briefing [2] Group 2: Product Development and R&D - The planning project department has established a dedicated R&D team of 6 personnel, focusing on the "Polypropylene Plant Liquid Catalyst Injection System Process Development" project [2] - The project aims to optimize product structure and enhance product variety through research on polymerization processes and catalyst dosage [2] Group 3: Production Capacity and Utilization - The company is currently operating all major production facilities as planned, with specific capacity utilization rates to be disclosed in regular reports [3][4] - The isobutylene hydrogenation unit has been expanded to a capacity of 35,000 tons/year [5] Group 4: Financial Performance and Growth Strategy - The company aims to enhance its core competitiveness by improving the C5/C9/propylene industrial chain and transitioning products towards functional, specialized, and high-end applications [3] - In 2024, the company invested in a 10,800 tons/year butadiene extraction unit, which has already been put into production [5] - The company is exploring new business areas to mitigate risks associated with its 100% revenue reliance on the chemical business [5] Group 5: Asset Management - The pharmaceutical division's assets were unsuccessfully listed for sale in 2017 and 2025, with plans to seek potential buyers in the future [6]